3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)

Core Viewpoint - Growth investors seek stocks with above-average financial growth, but identifying such stocks can be challenging due to their inherent risks and volatility [1] Group 1: Company Overview - Neurocrine Biosciences (NBIX) is highlighted as a recommended stock with a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 12.9%, with projected EPS growth of 36.4% this year, significantly surpassing the industry average of 19% [5] Group 2: Financial Metrics - Cash flow growth for Neurocrine is currently at 35.4%, well above the industry average of 3.2% [6] - The annualized cash flow growth rate over the past 3-5 years is 39.5%, compared to the industry average of 6.9% [7] Group 3: Earnings Estimates - There has been a positive trend in earnings estimate revisions for Neurocrine, with the Zacks Consensus Estimate for the current year increasing by 1.7% over the past month [8] - Neurocrine holds a Zacks Rank of 2 (Buy) and a Growth Score of B, indicating its potential as a solid choice for growth investors [10]